Independent consultant providing Bio-Pharma and partner companies with services in the areas of Business Strategy (Corporate, GTM Launch Strategy, Disease Area, Asset, Therapeutic Area), In-Market Commercialization, New Product Planning, Medical Affairs launch planing and Portfolio Planning- in Oncology, Immunology, CardioMetabolic & Rare diseases.

Hire four reports (VP-Dir level) to efficiently build & drive I-O strategy & launch planning (LRR1-3) through New Product Planning function. Establish group from scratch and build procedures to ensure sound decision-making. Develop robust GTM Launch strategy and US launch plans for PD-1 toripalimab, across several oncological indications via cross functional collaboration and executive engagements. Deliver strategic guidance on indication, tumor, target, asset selection, development program design decisions through development and execution of oncology portfolio strategy.
• Led corporate transition to novel oncology therapeutics; Led deal team, diligence and commercial assessments to help secure >$500M transformative multi-asset deal with Junshi Biosciences (including PD-1 toripalimab)
• Built, and hired for, New Product Planning (NPP) function to develop and execute PD-1 toripalimab US GTM launch/ pre-launch strategy across multiple indications, LCM strategy across multiple assets/

Created commercial entry strategy and informed development program strategy for CHS-131 in NASH and rare disease indications, including FRDA. Led campaign to secure Phase 2 VC and Large Pharma partnerfunding. Directed all facets of product positioning, investor presentations, DCF modelling, phase 2 design, and dose selection.
• Developed CHS-131 commercial and development strategy in combination with an SGLT-2inh to differentiate the asset in the marketplace by partnering with external Ols and internal board alignment
• Pitched and secured CHS-131 NASH investor financing to secure funding through Phase 2.
• Developed initial assessment of potential I-O Where To Play to help pivot Coherus to novel oncology

Devised strategic lifecycle management plans for phase three assets to meet targeted business objectives. Introduced new asset and disease areas within company in partnership with business development teams. Drove cross-functional alignment on Global DKD go to market strategy for Ask-1inh.
• Led strategic insights to inform development strategy for over five assets, from discovery through phase 3, with cross-functional alignment; directed business development strategy for immunology.

Conceptualized therapeutic area strategy and vision via business development, research and discovery, clinical development, LCM, and global commercialization. Spearheaded strategy across various programs (including rare disease) in PAH, NASH, DKD, UC, Crohn's, RA, RSV, Influenza, IPF, CF, COPD, Lupus, Sjogren's and others in collaboration with development team head. Led and motivated team of 12 personnel, including hiring five direct report hires from senior manager to Sr. director level, enhancing their performance. Built new therapeutic area, practices, teams, and structures to achieve shared vision and goals. Directed successful execution of various market access, HEOR, and publication strategies across multiple programs.
• Developed global GTM launch and market preparation strategies for filgotinib (JAK1-inh) in RA, UC, and Crohn's disease by assembling and leading large cross functional teams, in partnership with regional markets.
• Partnered with clinical and discovery TA heads

Developed and implemented commercial strategy for all respiratory programs, involving orphan. Steered MMP-9 development toward small/ high unmet need COPD populations. Led business case development for various programs (influenza, HRV, RSVnuc).
• Secured PARI pan-EU agreement on supply of nebulizers to markets.
• Doubled Cayston sales in 2013 by partnering with EU team to develop new strategy and messaging.
● Additional Experience